A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Exclusion Criteria

• •Has had a major surgery other than nephrectomy plus resection of preexisting metastases for M1 NED participants, within 4 weeks prior to randomization.
• •Has residual thrombus post nephrectomy in the vena renalis or vena cava.
• •Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
• •Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids.
• •Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
• •Received prior treatment with a cancer vaccine.
• •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
• •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
• •Has a history of brain or bone metastatic lesions.
• •Has severe hypersensitivity to study medication or any of the substances used to prepare the study medication.
• •Has an active autoimmune disease that has required systemic treatment in the past 2 years
• •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• •Has an active infection requiring systemic therapy
• •History of allogeneic tissue/solid organ transplant
• •Has not adequately recovered from major surgery or has ongoing surgical complications